Sangamo Therapeutics (SGMO)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	30.53 mm	30.53 mm	30.53 mm	30.53 mm	30.53 mm	30.53 mm
Cash burn (monthly)	3.11 mm	847.75 k	11.85 mm	9.33 mm	9.50 mm	6.35 mm
Cash used (since last report)	6.99 mm	1.91 mm	26.66 mm	21.00 mm	21.37 mm	14.28 mm
Cash remaining	23.54 mm	28.62 mm	3.86 mm	9.53 mm	9.15 mm	16.25 mm
Runway (months of cash)	7.6	33.8	0.3	1.0	1.0	2.6

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

SGMO institutional ownership history Ownership history

19.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	128	105	+21.9%
Opened positions	41	16	+156.3%
Closed positions	18	40	-55.0%
Increased positions	31	23	+34.8%
Reduced positions	30	36	-16.7%

13F shares	Current	Prev Q	Change
Total value	62.29 bn	47.64 bn	+30.8%
Total shares	64.74 mm	59.18 mm	+9.4%
Total puts	3.22 mm	1.17 mm	+175.8%
Total calls	1.72 mm	575.50 k	+198.4%
Total put/call ratio	1.9	2.0	-7.6%

Largest owners	Shares	Value	Change
Vanguard	9.37 mm	$9.56 bn	-2.3%
Wasatch Advisors	9.23 mm	$9.42 bn	-52.5%
BlackRock	5.19 mm	$5.30 bn	+43.1%
STT State Street	5.02 mm	$5.12 bn	+655.2%
BIIB Biogen	3.25 mm	$2.96 mm	0.0%
Renaissance Technologies	3.08 mm	$3.15 bn	-36.4%
Millennium Management	2.74 mm	$2.79 bn	+43.3%
Point72 Asset Management	2.27 mm	$2.32 bn	NEW
Geode Capital Management	2.21 mm	$2.26 bn	+3.4%
MS Morgan Stanley	1.88 mm	$1.92 bn	+433.3%

Largest transactions	Shares	Bought/sold	Change
Wasatch Advisors	9.23 mm	-10.21 mm	-52.5%
STT State Street	5.02 mm	+4.35 mm	+655.2%
Point72 Asset Management	2.27 mm	+2.27 mm	NEW
Marshall Wace	337.13 k	-2.02 mm	-85.7%
Ikarian Capital	1.86 mm	+1.86 mm	NEW
Renaissance Technologies	3.08 mm	-1.77 mm	-36.4%
Schonfeld Strategic Advisors	1.71 mm	+1.71 mm	NEW
BlackRock	5.19 mm	+1.56 mm	+43.1%
GS The Goldman Sachs Group, Inc.	1.61 mm	+1.54 mm	+2246.5%
MS Morgan Stanley	1.88 mm	+1.53 mm	+433.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SGMO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
24 Nov 25	Gregory D Davis	Common Stock	Payment of exercise	Dispose F	No	No	0.4166	723	301.20	193,791
24 Nov 25	Nathalie Dubois-Stringfellow	Common Stock	Payment of exercise	Dispose F	No	No	0.4166	2,544	1.06 k	719,804
24 Nov 25	Sandy Macrae	Common Stock	Payment of exercise	Dispose F	No	No	0.4166	7,488	3.12 k	2,049,534
24 Nov 25	Scott B. Willoughby	Common Stock	Payment of exercise	Dispose F	No	No	0.4166	2,035	847.78	702,086
24 Nov 25	Nikunj Jain	Common Stock	Payment of exercise	Dispose F	No	No	0.4166	578	240.79	245,717

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Intraday Session

21 Nov 25

Sangamo Therapeutics Biologics License Application Gets FDA's Acceptance For Isaralgagene Civaparvovec To Treat Fabry Disease

21 Nov 25

Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request for a rolling submission and review of the Biologics

This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

7 Nov 25

Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

7 Nov 25

Earnings Scheduled For November 6, 2025

6 Nov 25

Press releases

From Benzinga Pro

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

21 Nov 25

RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request